Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Breast Cancer

Free Subscription Articles published in Anticancer Res Retrieve available abstracts of 102 articles: HTML format

Single Articles

March 2023
1. SEMKOVA S, Nikolova B, Tsoneva I, Antov G, et al
   Redox-mediated Anticancer Activity of Anti-parasitic Drug Fenbendazole in Triple-negative Breast Cancer Cells.
   Anticancer Res. 2023;43:1207-1212.
   PubMed     Abstract available
   
   
   
2. COLLERY P, Michalke B, Lucio M, Varlet D, et al
   Plasma Rhenium and Selenium Concentrations After Repeated Daily Oral Administration of Rhenium(I)-diselenoether in 4T1 Breast Tumor-bearing Mice.
   Anticancer Res. 2023;43:1017-1023.
   PubMed     Abstract available
   
   
   
3. YOU D, Kim H, Jeong Y, Yoon SY, et al
   Chemokine (C-C motif) Ligand 2 Is Regulated Through the EGFR/Src Pathway in HER2-positive Breast Cancer Cells.
   Anticancer Res. 2023;43:1079-1089.
   PubMed     Abstract available
   
   
   
4. NADAI T, Narumi K, Mukai Y, Ueda H, et al
   5-Oxoproline Enhances 4-Hydroxytamoxifen-induced Cytotoxicity by Increasing Oxidative Stress in MCF-7 Breast Cancer Cells.
   Anticancer Res. 2023;43:1113-1120.
   PubMed     Abstract available
   
   
   
5. MAEDA A, Ando H, Irie K, Hashimoto N, et al
   Effects of ABCB1 and ABCG2 Polymorphisms on the Pharmacokinetics of Abemaciclib Metabolites (M2, M20, M18).
   Anticancer Res. 2023;43:1283-1289.
   PubMed     Abstract available
   
   
   
6. KO YC, Choi HS, Kim SL, Lee DS, et al
   Isophysalin A Inhibits the Stemness of Breast Cancer Cells Possibly via Stat3 and IL-6 Signaling.
   Anticancer Res. 2023;43:1091-1101.
   PubMed     Abstract available
   
   
   
7. VOUTSADAKIS IA, Stravodimou A
   Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies.
   Anticancer Res. 2023;43:967-981.
   PubMed     Abstract available
   
   
   
8. GEBBIA V, Martorana F, Sano MV, Valerio MR, et al
   Abemaciclib-associated Diarrhea: An Exploratory Analysis of Real-life Data.
   Anticancer Res. 2023;43:1291-1299.
   PubMed     Abstract available
   
   
   
9. IKEDA M, Kataoka Y, Taji T, Suwa H, et al
   Half Dose Pegfilgrastim for Patients With Breast Cancer During Chemotherapy: A Case-series.
   Anticancer Res. 2023;43:1373-1375.
   PubMed     Abstract available
   
   
   
10. BIMONTE S, Palma G, Cascella M, Cuomo A, et al
    Phytocannabinoids in Triple Negative Breast Cancer Treatment: Current Knowledge and Future Insights.
    Anticancer Res. 2023;43:993-1000.
    PubMed     Abstract available
    
    
    February 2023
11. TAKADA K, Kashiwagi S, Iimori N, Kouhashi R, et al
    Prognostic Impact of Smoking on Bevacizumab Combination Chemotherapy for Advanced Breast Cancer.
    Anticancer Res. 2023;43:849-856.
    PubMed     Abstract available
    
    
    
12. SCALIA G, Costanzo R, Viola A, Bonosi L, et al
    Intramedullary Spinal Cord Metastases from Breast Cancer: A Systematic Review.
    Anticancer Res. 2023;43:523-535.
    PubMed     Abstract available
    
    
    
13. GOTO W, Kashiwagi S, Iimori N, Kouhashi R, et al
    Eribulin Treatment Promotes Re-expression of Estrogen Receptor in Endocrine Therapy-resistant Hormone Receptor-positive Breast Cancer Cells.
    Anticancer Res. 2023;43:603-611.
    PubMed     Abstract available
    
    
    
14. BUONOMO OC, Materazzo M, Pellicciaro M, Iafrate G, et al
    Contrast-enhanced Ultrasound Using Intradermal Microbubble Sulfur Hexafluoride for Identification of Sentinel Lymph Nodes During Breast Cancer Surgery: A Clinical Trial.
    Anticancer Res. 2023;43:557-567.
    PubMed     Abstract available
    
    
    
15. YAMASHITA H, Hatanaka KC, Yamagishi K, Saito Y, et al
    Evaluation of 95-Gene Classifier of Formalin-fixed Paraffin-embedded Tissues in ER-positive, HER2-negative, and Node-negative Breast Cancer.
    Anticancer Res. 2023;43:707-711.
    PubMed     Abstract available
    
    
    
16. KOLBERG HC, Niesing H, Vaidya JS, Akpolat-Basci L, et al
    Breast Conserving Surgery in Combination With Targeted Intraoperative Radiotherapy Compared to Mastectomy for In-breast-tumor-recurrence.
    Anticancer Res. 2023;43:733-739.
    PubMed     Abstract available
    
    
    January 2023
17. KIMURA Y, Sasada S, Emi A, Masumoto N, et al
    (18)F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts Tumor Immune Microenvironment Function in Early Triple-negative Breast Cancer.
    Anticancer Res. 2023;43:127-136.
    PubMed     Abstract available
    
    
    
18. GOTO W, Kashiwagi S, Matsuoka K, Iimori N, et al
    Clinical Verification on the Predictors for Febrile Neutropenia in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
    Anticancer Res. 2023;43:247-254.
    PubMed     Abstract available
    
    
    
19. KATUWAL NB, Park N, Pandey K, Kang MS, et al
    Preclinical Platform Using a Triple-negative Breast Cancer Syngeneic Murine Model to Evaluate Immune Checkpoint Inhibitors.
    Anticancer Res. 2023;43:85-95.
    PubMed     Abstract available
    
    
    
20. LEE JH
    Phosphofructokinase 1 Platelet Isoform Enhances VEGF Expression in Part Through HIF-1alpha Up-regulation in Breast Cancer.
    Anticancer Res. 2023;43:75-84.
    PubMed     Abstract available
    
    
    
21. MIMOUN C, Legay L, Lorphelin H, Leveau-Vallier AS, et al
    Histological Risk Factors for Local Recurrence of Phyllodes Tumors of the Breast.
    Anticancer Res. 2023;43:143-147.
    PubMed     Abstract available
    
    
    
22. KIKUCHI M, Fujii T, Honda C, Tanabe K, et al
    Characteristics of Patients With Metastatic Breast Cancer Who Survived more than 10 Years.
    Anticancer Res. 2023;43:217-221.
    PubMed     Abstract available
    
    
    
23. COLBOURNE JRM, Toniolo JT, Diacon A, Lawrentschuk N, et al
    Following the Trend: A Comparative Analysis of Public Engagement and Funding for Annual Prostate and Breast Cancer Campaigns Using Google Trends.
    Anticancer Res. 2023;43:409-415.
    PubMed     Abstract available
    
    
    
24. TAKADA K, Kashiwagi S, Iimori N, Kouhashi R, et al
    Factor Analysis of Intraoperative Bleeding Loss and its Impact on Prognosis in Breast Cancer.
    Anticancer Res. 2023;43:191-200.
    PubMed     Abstract available
    
    
    December 2022
25. SUKNIAM K, Kasbi AA, Ali M, Popp K, et al
    Disparities in Time to Treatment for Breast Cancer.
    Anticancer Res. 2022;42:5813-5818.
    PubMed     Abstract available
    
    
    
26. SUZUKI K, Sasada S, Kimura Y, Emi A, et al
    Effect of Secondary Prophylactic G-CSF on the Occurrence of Febrile Neutropenia in Breast Cancer.
    Anticancer Res. 2022;42:5945-5949.
    PubMed     Abstract available
    
    
    
27. APESSOS A, Agiannitopoulos K, Pepe G, Tsaousis GN, et al
    Genetic Predisposition to Male Breast Cancer: A Case Series.
    Anticancer Res. 2022;42:5795-5801.
    PubMed     Abstract available
    
    
    
28. TANIGUCHI A, Kittaka N, Kanaoka H, Nakajima S, et al
    Risk of Abemaciclib-induced Liver Injury in Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer: A Retrospective Analysis.
    Anticancer Res. 2022;42:6027-6035.
    PubMed     Abstract available
    
    
    
29. KUBOTA Y, Han Q, Masaki N, Hozumi C, et al
    Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine Restriction.
    Anticancer Res. 2022;42:5819-5823.
    PubMed     Abstract available
    
    
    November 2022
30. MIZRAHI AG, Hamad H, Gugenheim A, Nisman B, et al
    Loss of Heterozygosity of BRCA1/2 as a Predictive Marker for Talazoparib Response.
    Anticancer Res. 2022;42:5257-5263.
    PubMed     Abstract available
    
    
    
31. TAKAHASHI E, Imai K, Fukuyama M, Terata K, et al
    Changes in Serum Trace Element Concentrations Before and After Surgery in Resectable Breast Cancer.
    Anticancer Res. 2022;42:5323-5334.
    PubMed     Abstract available
    
    
    
32. XIONG Y, Motomura H, Tamori S, Ozaki A, et al
    High Expression of CD58 and ALDH1A3 Predicts a Poor Prognosis in Basal-like Breast Cancer.
    Anticancer Res. 2022;42:5223-5232.
    PubMed     Abstract available
    
    
    
33. SCHMITZ V, Bauerschmitz G, Gallwas J, Grundker C, et al
    Suppression of G Protein-coupled Estrogen Receptor 1 (GPER1) Enhances the Anti-invasive Efficacy of Selective ERbeta Agonists.
    Anticancer Res. 2022;42:5187-5194.
    PubMed     Abstract available
    
    
    
34. SHOJI R, Tsuchie H, Nagasawa H, Hongo M, et al
    Intravascular Administration of Acridine Orange and Zoledronate in a Bone Metastasis Model of Breast Cancer.
    Anticancer Res. 2022;42:5357-5363.
    PubMed     Abstract available
    
    
    October 2022
35. KANAOKA H, Nagahashi M, Atake Y, Hattori A, et al
    Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors.
    Anticancer Res. 2022;42:4867-4878.
    PubMed     Abstract available
    
    
    
36. OZAWA H, Higuchi T, Fujimoto Y, Bun A, et al
    Total Lesion Glycolysis Levels as Predictive Indicators in Patients With Metastatic and Recurrent Breast Cancer Undergoing Endocrine Therapy With or Without CDK4/6 Inhibitor.
    Anticancer Res. 2022;42:4813-4824.
    PubMed     Abstract available
    
    
    
37. MORI T, Furukawa A, Bilal T, Ueda A, et al
    Simultaneous Detection and HER2 Profiling of Circulating Breast Cancer Cells in Clinical Patients Using a Rare Cell Sorter.
    Anticancer Res. 2022;42:4879-4886.
    PubMed     Abstract available
    
    
    
38. MUGURUMA M, Asaoka M, Teraoka S, Miyahara K, et al
    beta-Tubulin Isoforms Related to Docetaxel Sensitivity in 2D and 3D Cultured TNBC Cell Lines.
    Anticancer Res. 2022;42:4735-4742.
    PubMed     Abstract available
    
    
    September 2022
39. DO J, Chu J, Ahn J, Bae GE, et al
    Assessing Resection Margin Status in Breast-conserving Surgery Specimens: Comparison Among Gross Evaluation, Frozen Section Analysis, and Permanent Section Diagnosis in 725 Patients With Breast Cancer.
    Anticancer Res. 2022;42:4453-4460.
    PubMed     Abstract available
    
    
    
40. II H, Taniguchi K, Yoshiya T, Nohara Y, et al
    The gamma-Glutamylcyclotransferase Inhibitor Pro-GA Induces an Antiproliferative Effect Through the Generation of Mitochondrial Reactive Oxygen Species.
    Anticancer Res. 2022;42:4311-4317.
    PubMed     Abstract available
    
    
    
41. SON SW, Heo SH, Oh SS, Lee CH, et al
    Etoposide-induced MicroRNA-205-5p Suppresses Proliferation and Migration by Targeting ERBB4 in MCF-7 Cells.
    Anticancer Res. 2022;42:4265-4272.
    PubMed     Abstract available
    
    
    August 2022
42. TAKADA K, Kashiwagi S, Kouhashi R, Iimori N, et al
    The Effect of Smoking on Endocrine Therapy for Stage IV Hormone Receptor Positive Breast Cancer.
    Anticancer Res. 2022;42:3937-3946.
    PubMed     Abstract available
    
    
    
43. SHIMAZAKI A, Kubo M, Kurata K, Takao Y, et al
    CCND1 Copy Number Variation in Circulating Tumor DNA from Luminal B Breast Cancer Patients.
    Anticancer Res. 2022;42:4071-4077.
    PubMed     Abstract available
    
    
    
44. LIAO PA, Chu PY, Tan ZL, Hsu FT, et al
    STAT3 Inactivation and Induction of Apoptosis Associate With Fluoxetine-inhibited Epithelial-mesenchymal Transition and Growth of Triple-negative Breast Cancer In Vivo.
    Anticancer Res. 2022;42:3807-3814.
    PubMed     Abstract available
    
    
    
45. OGATA N, Toh U, Sudou T, Ogata S, et al
    Efficacy and Safety of Monthly Minodronate Therapy in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors.
    Anticancer Res. 2022;42:4139-4143.
    PubMed     Abstract available
    
    
    
46. KITANO S, Honda A, Itoi N, Lee T, et al
    Everolimus for Treating Hormone Receptor-positive Metastatic Breast Cancer Previously Treated With Cyclin-dependent Kinase 4/6 Inhibitors.
    Anticancer Res. 2022;42:3913-3919.
    PubMed     Abstract available
    
    
    
47. WANG YC, Wang ZH, Yen JH, Shen YC, et al
    The Contribution of Interleukin-8 Rs4073 Genotypes to Triple Negative Breast Cancer Risk in Taiwan.
    Anticancer Res. 2022;42:3799-3806.
    PubMed     Abstract available
    
    
    
48. VANNI G, Pellicciaro M, Materazzo M, Melaiu O, et al
    Neoadjuvant Treatment as a Risk Factor for Variation of Upper Limb Lymph Node Drainage During Axillary Reverse Mapping in Breast Cancer: A Prospective Observational Study.
    Anticancer Res. 2022;42:3879-3888.
    PubMed     Abstract available
    
    
    
49. TAKIMOTO R, Kamigaki T, Okada S, Ibe H, et al
    Efficacy of Adjuvant Immune-cell Therapy Combined With Systemic Therapy for Solid Tumors.
    Anticancer Res. 2022;42:4179-4187.
    PubMed     Abstract available
    
    
    July 2022
50. NOZAWA K, Takatsuka D, Endo Y, Horisawa N, et al
    Impact of Tumor Progression on Survival During Neoadjuvant Chemotherapy in Breast Cancer: A Cohort Study.
    Anticancer Res. 2022;42:3735-3742.
    PubMed     Abstract available
    
    
    
51. OZAKI A, Motomura H, Tamori S, Onaga C, et al
    High Expression of p62 and ALDH1A3 Is Associated With Poor Prognosis in Luminal B Breast Cancer.
    Anticancer Res. 2022;42:3299-3312.
    PubMed     Abstract available
    
    
    
52. SAITO Y, Takekuma Y, Takeshita T, Noguchi T, et al
    Risk Factor Analysis for the Occurrence of Severe Adverse Effects in Eribulin Treatment.
    Anticancer Res. 2022;42:3693-3700.
    PubMed     Abstract available
    
    
    
53. SAITO Y, Takekuma Y, Takeshita T, Sugawara M, et al
    Influence of Dose Reduction of Prophylactic Dexamethasone on Chemotherapy-induced Nausea and Anorexia in Patients Under 55 Years Old Treated With Anthracycline-containing Regimens.
    Anticancer Res. 2022;42:3753-3758.
    PubMed     Abstract available
    
    
    
54. SAEED MEM, Drif AI, Efferth T
    Biomarker Profiling Revealed Carcinoembryonic Antigen as a Target of Artesunate in a Ductal Breast Cancer Patient.
    Anticancer Res. 2022;42:3483-3494.
    PubMed     Abstract available
    
    
    
55. CHOI HY, Lee HJ, Moon KM, Moon DK, et al
    Up-regulation of CPNE1 Appears to Enhance Cancer Progression in HER2-positive and Luminal A Breast Cancer Cells.
    Anticancer Res. 2022;42:3445-3452.
    PubMed     Abstract available
    
    
    
56. NIGUMA K, Mamishin K, Naito Y, Nomura S, et al
    Impact of Older Age and Medico-social Factors on the Decision to Offer Adjuvant Chemotherapy to Patients With Breast Cancer.
    Anticancer Res. 2022;42:3743-3751.
    PubMed     Abstract available
    
    
    June 2022
57. RADES D, Narvaez CA, Dziggel L, Splettstosser L, et al
    Improvement of Sleep Disorders During a Course of Radiotherapy for Breast Cancer - Final Results of the Prospective Interventional RADIO-SLEEP Trial.
    Anticancer Res. 2022;42:3085-3089.
    PubMed     Abstract available
    
    
    
58. ROSENKAIMER S, Sieburg T, Winter L, Mavratzas A, et al
    Adverse Cardiovascular Effects of Anti-tumor Therapies in Patients With Breast Cancer: A Single-center Cross-sectional Analysis.
    Anticancer Res. 2022;42:3075-3084.
    PubMed     Abstract available
    
    
    
59. YEHIA ZA, Yoon J, Sayan M, Kumar S, et al
    Does the Use of BioZorb((R)) Result in Smaller Breast Seroma Volume?
    Anticancer Res. 2022;42:2961-2965.
    PubMed     Abstract available
    
    
    May 2022
60. CHUNG Y, Kim S, Kim HS, DO SI, et al
    High Receptor-interacting Serine/Threonine-protein Kinase 3 (RIP3) Expression Serves as an Independent Poor Prognostic Factor for Triple-negative Breast Carcinoma.
    Anticancer Res. 2022;42:2753-2761.
    PubMed     Abstract available
    
    
    
61. HAN M, Yamaguchi S, Onishi M, Fujii T, et al
    The MDM2 and CDKN2A Copy-number-variation Influence the TP53-signature-score in Wild-type TP53 Luminal Type Breast Cancer.
    Anticancer Res. 2022;42:2277-2288.
    PubMed     Abstract available
    
    
    
62. TAKEMURA M, Ikemura K, Yoshinami T, Toyozumi Y, et al
    Proton Pump Inhibitors Ameliorate Capecitabine-induced Hand-Foot Syndrome in Patients With Breast Cancer: A Retrospective Study.
    Anticancer Res. 2022;42:2591-2598.
    PubMed     Abstract available
    
    
    
63. TUOHINEN SS, Skytta T, Huhtala H, Virtanen V, et al
    Dynamic Integrated Backscatter Detects Radiotherapy-induced Cardiac Changes Better than Strain Analysis - A Prospective Three-year Study.
    Anticancer Res. 2022;42:2507-2517.
    PubMed     Abstract available
    
    
    
64. NISHIMURA M, Imaoka T, Daino K, Nishimura Y, et al
    Copenhagen Rats Display Dominantly Inherited Yet Non-uniform Resistance to Spontaneous, Radiation-induced, and Chemically-induced Mammary Carcinogenesis.
    Anticancer Res. 2022;42:2415-2423.
    PubMed     Abstract available
    
    
    April 2022
65. TANAKA M, Yamashita SI, Yoshinaga Y, Enomoto Y, et al
    Combination of DYRK2 and TERT Expression Is a Powerful Predictive Marker for Early-stage Breast Cancer Recurrence.
    Anticancer Res. 2022;42:2079-2085.
    PubMed     Abstract available
    
    
    
66. PARK HL, Yang B, Shin JE, Kim JY, et al
    Additional Excision Biopsy in Patients With Atypical Ductal Hyperplasia at Ultrasound-guided Vacuum-assisted Breast Biopsy.
    Anticancer Res. 2022;42:2159-2165.
    PubMed     Abstract available
    
    
    March 2022
67. KASHIWAGI S, Asano Y, Takada K, Goto W, et al
    Outcome Prediction After Neoadjuvant Chemotherapy (NAC) for Breast Cancer, Using Tumor-infiltrating Lymphocytes Within Fibrotic Foci of Tumor Stroma (FF-TILs).
    Anticancer Res. 2022;42:1421-1431.
    PubMed     Abstract available
    
    
    
68. OKAMOTO A, Funakoshi Y, Oe M, Takai R, et al
    Identification of Breast Cancer Stem Cells Using a Newly Developed Long-acting Fluorescence Probe, C5S-A, Targeting ALDH1A1.
    Anticancer Res. 2022;42:1199-1205.
    PubMed     Abstract available
    
    
    
69. DANTAS FT, Felix-Silva PH, Angotti-Carrara HH, Dos-Reis FJC, et al
    A New Method for Obtaining Tumor Interstitial Fluid Applied to Cytokine Analysis of Breast Carcinoma Samples.
    Anticancer Res. 2022;42:1327-1332.
    PubMed     Abstract available
    
    
    February 2022
70. SEKI H, Sakurai T, Sakurada A, Kinoshita T, et al
    Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer.
    Anticancer Res. 2022;42:1099-1106.
    PubMed     Abstract available
    
    
    
71. ALEXOPOULOS A, Karanikiotis C, Ardavanis A, Boukovinas I, et al
    Safety and Efficacy of RAD001 (Everolimus) Administered Upon Relapse During or After Adjuvant Treatment in Post-menopausal Women With Hormone Receptor Positive, HER2/neu Negative Locally Advanced or Metastatic Breast Cancer (CRAD001JGR08 "MELPOMENI" s
    Anticancer Res. 2022;42:1031-1041.
    PubMed     Abstract available
    
    
    
72. WAZIR U, Patani N, Heeney J, Mokbel K, et al
    Pre-pectoral Immediate Breast Reconstruction Following Conservative Mastectomy Using Acellular Dermal Matrix and Semi-smooth Implants.
    Anticancer Res. 2022;42:1013-1018.
    PubMed     Abstract available
    
    
    
73. GOTO W, Kashiwagi S, Takada K, Asano Y, et al
    Utility of Follow-up With Absolute Lymphocyte Count in Patients Undergoing Eribulin Treatment for Early Detection of Progressive Advanced or Metastatic Breast Cancer.
    Anticancer Res. 2022;42:939-946.
    PubMed     Abstract available
    
    
    
74. NIEDER C, Ressheim J, Haukland EC, Mannsaker B, et al
    Implementation of Locoregional Adjuvant Radiotherapy for Breast Cancer in a Rural Healthcare Region: Toxicity Outcomes in the Initial Cohort.
    Anticancer Res. 2022;42:923-928.
    PubMed     Abstract available
    
    
    
75. COMSA S, Ceausu AR, Popescu R, Cimpean AM, et al
    Patterns of Tumor Vasculogenesis on a Chick Embryo Chorioallantoic Membrane In Vivo Model of Breast Cancer.
    Anticancer Res. 2022;42:877-883.
    PubMed     Abstract available
    
    
    
76. HO CY, Hu DW, Chen BR, Yang CC, et al
    Snail Mucus Enhances Chemosensitivity of Triple-negative Breast Cancer Via Activation of the Fas Pathway.
    Anticancer Res. 2022;42:845-855.
    PubMed     Abstract available
    
    
    
77. GOHNO T, Hanamura T, Kurosumi M, Takei H, et al
    One DNA Methylation Regulates CHIP Gene Expression of Human Breast Cancer and Predicts Recurrence.
    Anticancer Res. 2022;42:759-766.
    PubMed     Abstract available
    
    
    
78. SONG C, Kendi AT, Lowe VJ, Lee S, et al
    The A20/TNFAIP3-CDC20-CASP1 Axis Promotes Inflammation-mediated Metastatic Disease in Triple-negative Breast Cancer.
    Anticancer Res. 2022;42:681-695.
    PubMed     Abstract available
    
    
    
79. MOKBEL K, Mokbel K
    The Role of Community Pharmacists in Addressing Medication-related Issues for Breast Cancer Patients Receiving Adjuvant Endocrine Therapy.
    Anticancer Res. 2022;42:661-666.
    PubMed     Abstract available
    
    
    January 2022
80. MAZAKI AI, Yamauchi K, Orita S, Inage K, et al
    Nerve Growth Factor in Breast Cancer Cells Promotes Axonal Growth and Expression of Calcitonin Gene-related Peptide in a Rat Model of Spinal Metastasis.
    Anticancer Res. 2022;42:581-587.
    PubMed     Abstract available
    
    
    
81. HENRIQUES PALMA GB, Kaur M
    Cholesterol Depletion Modulates Drug Resistance Pathways to Sensitize Resistant Breast Cancer Cells to Tamoxifen.
    Anticancer Res. 2022;42:565-579.
    PubMed     Abstract available
    
    
    
82. HOSOYA K, Nosaka K, Sakabe T, Wakahara M, et al
    Clinical Significance of Serglycin Expression in Human Breast Cancer Patients.
    Anticancer Res. 2022;42:279-285.
    PubMed     Abstract available
    
    
    
83. MEIROVITZ A, Nisman B, Allweis TM, Carmon E, et al
    Thyroid Hormones and Morphological Features of Primary Breast Cancer.
    Anticancer Res. 2022;42:253-261.
    PubMed     Abstract available
    
    
    
84. ASANO Y, Kashiwagi S, Takada K, Ishihara S, et al
    Clinical Significance of Expression of Immunoadjuvant Molecules (LAG-3, TIM-3, OX-40) in Neoadjuvant Chemotherapy for Breast Cancer.
    Anticancer Res. 2022;42:125-136.
    PubMed     Abstract available
    
    
    
85. SAYAN M, Vergalasova I, Jan I, Kumar S, et al
    Toxicities and Locoregional Control After External Beam Chest Wall and/or Regional Lymph Node Re-irradiation for Recurrent Breast Cancer.
    Anticancer Res. 2022;42:93-96.
    PubMed     Abstract available
    
    
    
86. SAYAN M, Yehia ZA, Jan I, Gupta A, et al
    Adaptive Lumpectomy Boost Planning Can Reduce Normal Tissue Exposure in Patients Receiving Hypofractionated Whole Breast Irradiation.
    Anticancer Res. 2022;42:53-57.
    PubMed     Abstract available
    
    
    
87. TAKADA K, Kashiwagi S, Asano Y, Goto W, et al
    The Effect of Smoking on Progression from Ductal Carcinoma In Situ to Invasive Ductal Breast Carcinoma: A Retrospective Study.
    Anticancer Res. 2022;42:311-320.
    PubMed     Abstract available
    
    
    December 2021
88. MAMISHIN K, Naito Y, Nomura S, Ogawa G, et al
    Comparison of Treatment Completion Rate Between Conventional and Dose-dense Doxorubicin and Cyclophosphamide (AC) Followed by a Taxane in Patients With Breast Cancer: A Propensity Score-matched Analysis.
    Anticancer Res. 2021;41:6217-6224.
    PubMed     Abstract available
    
    
    
89. HONG SE, Jin HO, Kim SM, Jang SK, et al
    miR-3188 Enhances Sensitivity of Breast Cancer Cells to Ionizing Radiation by Down-regulating Rictor.
    Anticancer Res. 2021;41:6169-6176.
    PubMed     Abstract available
    
    
    
90. MOTOMURA H, Tamori S, Yatani MA, Namiki A, et al
    GLO 1 and PKClambda Regulate ALDH1-positive Breast Cancer Stem Cell Survival.
    Anticancer Res. 2021;41:5959-5971.
    PubMed     Abstract available
    
    
    
91. ACUNA UM, Ezzone N, Rakotondraibe LH, Carcache DE Blanco EJ, et al
    Activity in MCF-7 Estrogen-sensitive Breast Cancer Cells of Capsicodendrin from Cinnamosma fragrans.
    Anticancer Res. 2021;41:5935-5944.
    PubMed     Abstract available
    
    
    
92. KANGA KJW, Mendonca P, Soliman KFA, Ferguson DT, et al
    Effect of Diallyl Trisulfide on TNF-alpha-induced CCL2/MCP-1 Release in Genetically Different Triple-negative Breast Cancer Cells.
    Anticancer Res. 2021;41:5919-5933.
    PubMed     Abstract available
    
    
    
93. NOMURA T, Kurebayashi J, Moriya T, Saito W, et al
    A Case of Rare Matrix-producing Triple-negative Breast Carcinoma for Which Drug Response in a Patient-derived Orthotopic Xenograft Mouse Model Was Correlated With Patient Response.
    Anticancer Res. 2021;41:6191-6197.
    PubMed     Abstract available
    
    
    
94. COLLERY P, Veena V, Desmaele D, Harikrishnan A, et al
    Effects of Rhenium(I)-diselenoether and of its Diselenide Ligand on the Production of Cathepsins B and S by MDA-MB231 Breast Malignant Cells.
    Anticancer Res. 2021;41:5997-6001.
    PubMed     Abstract available
    
    
    November 2021
95. TOKISAWA H, Aruga T, Honda Y, Ishiba T, et al
    Safety and Effectiveness of Areola-sparing Mastectomy for Breast Cancer With Intraductal Lesions.
    Anticancer Res. 2021;41:5723-5728.
    PubMed     Abstract available
    
    
    
96. PIANKA J, Gruba N, Kitowska K, Mieczkowski K, et al
    Simplified Theta-defensin [Ser(3,7,12,16)] RTD-2 Analog Is Involved in Proteasomal Degradation Pathway in Breast Cancer.
    Anticancer Res. 2021;41:5415-5423.
    PubMed     Abstract available
    
    
    
97. VANNI G, Caiazza G, Materazzo M, Storti G, et al
    Erector Spinae Plane Block Versus Serratus Plane Block in Breast Conserving Surgery: Alpha Randomized Controlled Trial.
    Anticancer Res. 2021;41:5667-5676.
    PubMed     Abstract available
    
    
    
98. VANNI G, Pellicciaro M, Sadri A, Tacconi F, et al
    Pre-pectoral Breast Reconstruction Does Not Affect Early Immunological Response: A BIAL 2.20 Study Subanalysis.
    Anticancer Res. 2021;41:5657-5665.
    PubMed     Abstract available
    
    
    October 2021
99. FRIEDRICH RE, Madani E
    Consolidation of Tumorous Mandibular Ramus Defect During Denosumab Treatment for Rapidly Progressive Metastatic Breast Cancer.
    Anticancer Res. 2021;41:5081-5087.
    PubMed     Abstract available
    
    
    
100. VAHAAHO N, Hakamies-Blomqvist L, Blomqvist C, Kellokumpu-Lehtinen PL, et al
     Sense of Coherence as Predictor of Quality of Life in Early Breast Cancer Patients.
     Anticancer Res. 2021;41:5045-5052.
     PubMed     Abstract available
     
     
     
101. TAKASHIMA T, Nishimura S, Kawajiri H, Mizuyama Y, et al
     An Exploratory Phase II Study of Eribulin Re-challenge After Short Term Therapy of 5-Fluorouracil for HER2 Negative, Advanced or Recurrent Breast Cancer.
     Anticancer Res. 2021;41:5007-5014.
     PubMed     Abstract available
     
     
     
102. WU NF, Yamamoto J, Aoki Y, Masaki N, et al
     The Combination of Cisplatinum and Doxorubicin Regressed Primary Osteosarcoma of the Breast in a PDOX Mouse Model.
     Anticancer Res. 2021;41:4715-4718.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: